<DOC>
	<DOCNO>NCT02723734</DOCNO>
	<brief_summary>The primary purpose study determine whether tumor test recently develop GenomeDx Biosciences know Decipher® predict aggressive prostate cancer accuracy African-American men ( AAM ) non-African-American men ( NAAM ) . The Decipher® test develop sample derive mainly men European origin little known performance AAM . It important study whether test use AAM known experience high rate prostate cancer well death prostate cancer . The use Decipher® test result predict well patient treatment may make possible doctor distinguish aggressive disease low risk prostate cancer modify treatment accordingly . Thus , patient need additional therapy may spar unnecessary side effect risk may provide aggressive therapy improve survival . This study do learn whether Decipher test really affect outcome .</brief_summary>
	<brief_title>Validation Study Impact Decipher® Testing - VANDAAM Study</brief_title>
	<detailed_description>This multisite , prospective validation trial . Based population consist 25 % AAM 75 % NAAM , investigator actively recruit participant aim achieve 1:1 enrollment ratio AAM NAAM . To achieve , low risk AAM accrue first match NAAM enrol . NAAM men match AAM prostate specific antigen ( PSA ) diagnosis . There treatment intervention beyond standard care ( SOC ) , therefore participant allow choose definitive treatment option . The intent enroll low risk high volume disease ( burden ) patient limit accrual patient would select active surveillance ( AS ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Adult patient Karnofsky Performance Status &gt; 70 Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Pathologically ( histologically ) proven diagnosis prostate cancer ( PCa ) undergo first line treatment Meet National Comprehensive Cancer Network ( NCCN ) criteria either : Low risk PCa ( define Gleason score 6 ≥ 3 core ; Tstage T1c T2a ) ; Intermediate risk PCa ( define Gleason score 7 , prostatic specific antigen ( PSA ) ≥ 10 ng/ml &amp; &lt; 20 ng/ml , Tstage ≤ T2c ) Eligible either radical prostatectomy ( RP ) definitive radiation therapy ( RT ) ( +/ shortterm androgen deprivation therapy ( ADT ) ) Age &gt; 18 year Biopsy specimen available Inability acquire biopsy prostatectomy tissue History prior PCa direct chemotherapy pelvic irradiation ( prior study enrollment ) Documented distant metastatic disease pelvic lymphadenopathy Prior radical prostatectomy ( RP ) cryosurgery prostate cancer bilateral orchiectomy Targeted active surveillance diagnostic biopsy Selecting ADT alone diagnostic biopsy On active surveillance &gt; 6 month diagnosis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Decipher®</keyword>
	<keyword>African-American men</keyword>
	<keyword>prostate</keyword>
	<keyword>low risk PCa</keyword>
	<keyword>intermediate risk PCa</keyword>
	<keyword>genomic classifier ( GC )</keyword>
</DOC>